Mary Wilson
Well-known member
Sarah Neville in London and Donato Paolo Mancini in Rome
AN HOUR AGO
Pfizer has criticised the UK’s decision to lengthen the gap between doses of its Covid-19 vaccine, saying the “safety and efficacy” of the new schedule had not been evaluated, as infections and hospitalisations continued to soar across the UK.
The rare intervention by the US pharma company came amid growing controversy over the move, with doctors complaining that they were having to cancel appointments and reassure anxious patients who had previously been told they needed the second dose to keep them safe.
“[Our] study . . . was designed to evaluate the vaccine’s safety and efficacy following a two-dose schedule, separated by 21 days,” the company said. “The safety and efficacy of the vaccine has not been evaluated on different dosing schedules as the majority of trial participants received the second dose within the window specified in the study design.”
The new dosing guidelines, approved by the UK’s joint committee on vaccination and immunisation and unveiled on Wednesday, allow the second dose of both the vaccine that Pfizer developed with BioNTech, and the newly approved Oxford/AstraZeneca vaccine, to be delivered as much as three months after the first.
https://www.ft.com/content/d97c72c5-ed23-4c2b-bf1c-9cc10b21f007
AN HOUR AGO
Pfizer has criticised the UK’s decision to lengthen the gap between doses of its Covid-19 vaccine, saying the “safety and efficacy” of the new schedule had not been evaluated, as infections and hospitalisations continued to soar across the UK.
The rare intervention by the US pharma company came amid growing controversy over the move, with doctors complaining that they were having to cancel appointments and reassure anxious patients who had previously been told they needed the second dose to keep them safe.
“[Our] study . . . was designed to evaluate the vaccine’s safety and efficacy following a two-dose schedule, separated by 21 days,” the company said. “The safety and efficacy of the vaccine has not been evaluated on different dosing schedules as the majority of trial participants received the second dose within the window specified in the study design.”
The new dosing guidelines, approved by the UK’s joint committee on vaccination and immunisation and unveiled on Wednesday, allow the second dose of both the vaccine that Pfizer developed with BioNTech, and the newly approved Oxford/AstraZeneca vaccine, to be delivered as much as three months after the first.
https://www.ft.com/content/d97c72c5-ed23-4c2b-bf1c-9cc10b21f007